Navigation Links
Swedish-American Life Science Summit (SALSS) to Address Major Issues Including Healthcare Reform, Synthetic Biology and Innovative Financing for Biotechs
Date:8/17/2009

STOCKHOLM, Aug. 17 /PRNewswire/ -- The Swedish-American Life Science Summit (SALSS) today announced that U.S. Representative Diana DeGette (D. Colo) will be a keynote speaker at the fifth annual summit, which opens in Stockholm on August 20, 2009. Ms. DeGette, co-sponsor of the pioneering Stem Cell Research Enhancement Act in 2007 and an advisor to President Obama on healthcare reform, will help open SALSS, a vital showcase for the Swedish life sciences and a forum for bringing together leading scientists, investors and corporate executives from both the U.S. and Swedish life science communities.

Other headliners at SALSS include Prof. Jay Keasling of U.C. Berkley, who was awarded Discover's Scientist of the Year prize for making the biggest impact in science. Prof. Keasling is a leader in the area of synthetic biology and heads OneWorld Health, a non- profit company that develops drugs for neglected infectious diseases.

Other SALSS participants include: Prof. Mathias Uhlen, founder of the Swedish Human Protein Atlas; Prof. Harriet Wallberg-Henriksson, President of Karolinska Institutet; Dr. William A. Haseltine, founder of Human Genome Sciences; Dr. Stephen Friend, President of Sage Bionetworks; Scott Sarazen, Global Life Sciences Markets Leader, Ernst & Young; and Dr. Anders Ekblom, Executive V.P. AstraZeneca, and many more exciting speakers.

The summit will be opened by Princess Christina of Sweden, Mrs. Magnuson, who is the former Chairperson of the Swedish Red Cross.

Among the group of the new promising life sciences companies is Cell Therapy Ltd, a company initiated by Nobel Laureate, Sir Martin Evans, a pioneer in embryonic stems cells.

Barbro Ehnbom, Founder and Chairman of SALSS states: "We are experiencing a major paradigm shift in healthcare. The rules have changed. By bringing together two of the major life sciences research communities -- US and Sweden -- and engaging their thought leaders in wide-ranging discussions, SALSS once again expects to be a major catalyst for understanding and profiting from cutting edge developments in life sciences."

Members of the press wishing to attend the conference or conduct specific interviews with key speakers please contact Project Manager Claudia Olsson +46 (0) 702 792 524 or email claudia@swedishamericanlifescience.com. For conference details please contact Program Advisor Udayan Gupta +1 917 497 8407 or email udayangupta115@gmail.com. Or, contact Leslie Wolf-Creutzfeldt of Grayling, 646-284-9472, or fax: 646-284-9485.

ABOUT SALSS 2009

SALSS has an invitation-only format that features some of the best known Life Science Executives in the industry. Previous SALSS participants have included; Mr. Frederick Frank, former Vice Chairman of Lehman Brothers, Nobel Laureate Arvid Carlsson and Dr. Jacob Wallenberg, Chairman of Investor AB.

Barbro Ehnbom, founder of SALSS, was one of the first female executives in the US pharmaceutical industry, and a top analyst in Wall Street, followed by many years of investment banking. As a long time board member of the Swedish-American Chamber of Commerce and Chairman Emeritus of the Swedish Economist Group in New York, she has 25 years experience of organizing events between the two countries

A full program is available on www.swedishamericanlifescience.com.


'/>"/>
SOURCE The Swedish-American Life Science Summit
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
5. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
6. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
7. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
8. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
9. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression ... guides is transformative for performing systematic gain-of-function studies. , This complement to ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:3/30/2017)... , March 30, 2017 The research ... system for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D ... a new realm of speed and accuracy for use in identification, ... an affordable cost. ... ...
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
Breaking Biology News(10 mins):